Last reviewed · How we verify

NCT03077269

Understanding Coagulation and Inflammation in Burns

Terminated Last updated 13 February 2026
What this trial tests

trial in Burns in 120 participants. Terminated before completion.

Timeline
1 May 2016
Primary endpoint
19 May 2025
19 May 2025

Quick facts

Lead sponsorUniversity of Rochester
StatusTerminated
Study typeOBSERVATIONAL
Enrollment120
Start date1 May 2016
Primary completion19 May 2025
Estimated completion19 May 2025
Sites1 location across United States

Conditions studied

Sponsor

University of Rochester

Who can join

Adults 18 to 110, any sex, with Burns. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to understand what happens to platelets and blood clotting factors in burn patients over time. This study will also examine the role of microparticles (MPs), nanoparticles (NPs), and micro RNA in burns. The investigators will be looking at small particles of cells that are released into the blood. These particles have been found to be important in a variety of different diseases. The investigators believe that MPs, NPs, and micro RNA may play a role in development of inflammation, and infections in burn patients. Thus, hopefully, this study will help understand how to minimize transfusions and bleeding in burn patients as well as how to reduce inflammation and infections in burn patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Burns

Currently open trials in the same condition.

Other University of Rochester trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03077269.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing